Aptus Pharma Peer Comparison

BSE: 544529

₹320.70

₹6.25 (1.99%)

As on 28-Aug-2026IST

Market cap

₹550 Cr

Revenue (TTM)

₹47 Cr

P/E Ratio

119.1

P/B Ratio

16.4

Div. Yield

0 %

Edit

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	550	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	47	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	4.62	414.00	288.22	-371.81	387.35
Net Margin (%)	9.89	11.23	14.79	-3.93	26.01
RoE (%)	30.48	8.38	29.77	-3.85	25.18
Price to Earnings	119.05	78.49	103.71	--	69.57
Price-To-Book	16.35	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	46.57	3,373.00	1,753.96	8,869.08	--
Total Income	46.71	3,510.00	1,762.66	9,111.51	--
Total Expenditure	39.12	2,747.00	1,354.69	7,976.59	--
EBITDA	7.45	626.00	399.26	892.49	--
Depreciation	0.41	227.00	45.26	831.24	--
EBIT	7.05	399.00	354.00	61.25	--
Interest	0.81	213.00	42.17	340.80	--
Other Income	0.13	137.00	8.70	242.43	--
Exceptional Items	--	-85.00	--	-196.14	--
Profit before Tax	6.37	238.00	320.53	-176.06	--
Provision for Tax	1.75	39.00	73.80	149.88	--
Profit after Tax	4.62	199.00	246.74	-325.94	--

Liabilities (₹ Cr)

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	23.35	4,940.00	1,288.82	8,162.62	--
Minority Interest	--	341.00	0.00	--	--
Non-Current Liabilities	0.79	1,235.00	189.02	4,529.41	--
Current Liabilities	19.31	1,622.00	835.87	4,874.74	--
Total Liabilities	43.53	8,578.00	2,326.71	17,723.32	--

Assets (₹ Cr)

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	8.21	5,441.00	631.90	10,258.66	--
Current Assets	35.24	2,606.00	1,681.81	7,308.11	--
Total Assets	43.53	8,578.00	2,326.71	17,723.32	--
Total Debt*	7.18	2,125.00	259.37	5,495.48	--
Net Current Assets	15.93	984.00	845.94	2,433.37	--
Contingent Liabilities	--	768.26	19.09	95.72	--

Cashflow (₹ Cr)

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-5.60	390.00	205.05	1,652.60	--
Cash Flow from Investing Activities	-6.37	-241.00	-409.72	-826.03	--
Cash from Financing Activities	7.79	-54.00	283.07	-38.98	--
Net Cash Inflow / Outflow	-4.19	95.00	78.39	787.59	--

Ratios

Profitability Ratios

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	30.01	6.79	29.22	1.24	--
ROE (%)	30.48	4.29	27.84	-4.04	--
ROA (%)	14.15	2.53	13.11	-1.98	--
EBIT Margin (%)	16.29	22.62	23.26	12.80	--
Net Margin (%)	9.89	5.67	14.00	-3.58	--
Cash Profit Margin (%)	10.51	10.98	7.71	4.80	--

Growth Ratios

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	89.65	11.99	36.57	-3.08	--
EBIT Growth (%)	53.97	67.69	52.29	-28.15	--
Net Profit Growth (%)	49.05	449.12	83.64	-457.66	--
EPS Growth (%)	443.21	553.20	71.44	-456.91	--
Book Value Growth (%)	235.14	13.47	144.31	0.33	--

Valuation Ratios

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	20.74	89.54	51.69	0.00	--
Price / Book Value	10.26	3.87	10.14	2.24	--
Dividend Yield (%)	0.00	0.00	0.19	0.00	--
EV/EBITDA	32.38	27.45	31.05	19.72	--
Market Cap (₹ Cr)	239.52	19,071.62	12,753.19	18,108.89	--

Solvency Ratios

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.31	0.43	0.21	0.68	--
Short term debt to equity ratio	0.28	0.09	0.05	0.09	--
Current Ratio	1.83	1.61	2.01	1.50	--
Quick Ratio	1.12	1.06	1.14	0.87	--
Interest Coverage	8.92	2.12	8.60	0.48	--

Operating Efficiency Ratios

	Aptus Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	40.28	17.43	29.00	24.33	--
Asset Turnover	1.47	0.49	2.01	0.64	--
Receivable days	93.10	58.75	40.13	78.20	--
Inventory Days	78.71	75.82	60.29	93.30	--
Payable days	80.80	186.21	232.47	226.14	--
Cash Conversion Cycle	91.00	-51.64	-132.04	-54.64	--

Annual
Quarterly